Description

GSK’s 35Pharma Acquisition: Hidden Synergies That Could Boost Margins And Growth!

Pharmaceutical dealmaking at GSK has accelerated meaningfully under CEO Luke Miels, and the proposed $950 million acquisition of Canada-based 35Pharma marks the latest step in that strategic push. The transaction, centered on early-stage cardiopulmonary drug candidate HS235, comes as GSK continues to rebalance its portfolio toward specialty medicines, long-acting biologics, and high-growth therapeutic categories. While the company has deliberately avoided direct participation in the crowded GLP-1 obesity market, it has been expanding its exposure to obesity-related diseases such as MASH and cardiometabolic disorders. Pulmonary hypertension, which affects an estimated 82 million people globally and is projected to reach an $18 billion market by 2032, sits at the intersection of cardiology, metabolism, and inflammation.